Inhibition of breast cancer growth and invasion by single-minded 2s

Hyeong-Il Kwak1, Tanya Gustafson, Richard P Metz

  • 1Department of Integrated Biosciences, College of Veterinary Medicine, Texas A&M University, College Station, TX 77843-4458, USA.

Carcinogenesis
|July 15, 2006
PubMed

Insights

The Single-minded 2 short (SIM2s) variant acts as a tumor suppressor, inhibiting breast cancer cell growth and metastasis. Its downregulation in breast cancer suggests a protective role against the disease.

Area of Science:

  • Genetics
  • Molecular Biology
  • Oncology

Background:

  • Single-minded 2 (SIM2) is a transcription factor linked to Down syndrome (DS).
  • Women with DS exhibit a reduced incidence of breast cancer, potentially due to chromosome 21 gene dosage effects.
  • A SIM2 splice variant, SIM2 short (SIM2s), is investigated for its role in breast cancer.

Purpose of the Study:

  • To investigate the expression and function of SIM2s in breast cancer.
  • To determine if SIM2s possesses tumor suppressive properties.

Main Methods:

  • Differential expression analysis of SIM2s in breast cell lines and human samples.
  • Functional assays in breast cancer cells (MDA-MB-435) to assess proliferation, anchorage-independent growth, and invasion.
  • Analysis of SIM2s' effect on matrix metalloprotease-3 (MMP-3) expression.

Main Results:

  • SIM2s is differentially expressed in breast cancer cell lines and downregulated in human breast cancer tissues.
  • Restoring SIM2s expression in cancer cells significantly reduced proliferation, anchorage-independent growth, and invasiveness.
  • SIM2s directly repressed MMP-3 expression, a key mediator of breast cancer metastasis.

Conclusions:

  • SIM2s exhibits significant breast tumor suppressive activity.
  • The findings suggest SIM2s could be a potential therapeutic target for breast cancer treatment.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...